Sugammadex

From WikiAnesthesia
Revision as of 08:00, 21 February 2021 by Chris Rishel (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Sugammadex
Trade names Bridion
Sugammadex.svg
Clinical data
Uses Reversal of neuromuscular blockade from rocuronium and vecuronium
Contraindications Renal impairment
Routes of administration Intravenous
Dosage Based upon response to train-of-four stimulation:
  • 2+ twitches: 2 mg/kg
  • 1-2 posttetanic twitches: 4 mg/kg
Reversal immediately after administration of rocuronium 1.2 mg/kg: 16 mg/kg
Pharmacodynamics
Mechanism of action Encapsulation of rocuronium or vecuronium
Adverse effects Bradycardia, may interfere with hormonal contraceptives
Pharmacokinetics
Physical and chemical data
Formula C72H112O48S8
Molar mass 2002.12 g/mol

Sugammadex is used to reverse neuromuscular blockade from rocuronium and vecuronium.

Uses

If a patient requires reparaylsis after administration of sugammadex (up to 4 mg/kg), rocuronium or vecuronium can be re-administered after a minimum waiting time.[1]

Drug and dose to be administered Minimum waiting time
Rocuronium 1.2 mg/kg 5 minutes
Rocuronium 0.6 mg/kg or

vecuronium 0.1 mg/kg

4 hours

Contraindications

Absolute contraindications

Precautions

Pharmacology

Pharmacodynamics

Mechanism of action

Adverse effects

Pharmacokinetics

Chemistry and formulation

History

References

  1. "BRIDION® (sugammadex) Injection Drug Label (FDA)" (PDF).